Frequency of Ocular Manifestations in Systematic Lupus Erythematosus Patients in a Tertiary care Hospital in Dhaka, Bangladesh.
Purpose
To determine the ocular involvement in SLE patients.
Methods
This cross sectional descriptive study was conducted among 110 patients, who were diagnosed cases of SLE by the Rheumatologists .The study duration was 7months (June 2019 to January 2020). Sample collection method was purposive sampling and data was collected by checklist. All patients underwent a comprehensive ophthalmic examination including Visual Acuity test, Slit-lamp examination of anterior chamber, Fluorescein staining,Schirmer-1test, Glodmann applanation tonometry ,Fundoscopy to assess retina, choroid and optic disc.
Results
A total of 110 patients (90 female and 20 male) were enrolled in this study .The mean age was 29.02+_ 11.53 SD and the mean disease duration was 10.5 years.76 patients (69%) were found to have ocular involvement. The most frequent manifestation was Dry eye syndrome (35%), followed by Retinal arteriolar narrowing (18.1%), SLE retinopathy (12.7%), Disc oedema (10.9%),Episcleritis (9%). Retinal vasculitis, follicular conjunctivitis and posterior sub-capsular cataract showed similar frequency (7.2%). Anterior uveitis and Optic atrophy was found in 4 patients. Other findings like Peri-orbital oedema , glaucoma ,vitreous haemorrhage and choroidopathy illustrated similar results (1.8%).
Conclusion
Ocular manifestations in SLE are often associated with active systemic inflammation and can also be an useful indicator of underlying systemic disease activity . Keep in view its wide range of involvement and potential blinding nature, a multi disciplinary approach and appropriate co-management strategies are crucial to reduce SLE associated ocular morbidities.
Conflict of interest
No
Authors 1
Last name
AFRIN
Initials of first name(s)
M
Department
Ophthalmogy, Green Life Medical College, Dhaka-1205. Bangladesh.
City
Dhaka
Country
Bangladesh
This website uses cookies to ensure you get the best experience on our website.
Learn more